Abstract
Since December 2019, the Coronavirus Disease 2019 (COVID-19) pandemic has become a non-neglectable context for the whole healthcare system. Under the background of COVID-19, the detection and diagnosis of malaria cases are under challenge. Here, we reported a COVID-19 and malaria co-infection traveler who has a long living history in Cameroon. The case was administered with dihydroartemisinin and piperaquine tablets for malaria, Lopinavir and Ritonavir tablets, Arbidol, recombinant human interferon α-2b and Compound Maxing Yifei mixture for COVID-19, and Zolpidem Tartrate tablets, Diazepam, Paroxetine Hydrochloride tablets, Thymosin α1, and Lianhua Qinwen Jiaonang during the second hospitalization of the patient since the patient has a certain level of anxiety and insomnia with no evidence of inflammatory reactions. After being tested negative two times for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 48 h, the patient met China’s COVID-19 discharge standards and was discharged with stable vital signs and mental state. Since most countries in the sub-Saharan region have a fragile health system, co-infection for both Plasmodium and SARS-CoV-2 may not be uncommon, and raise a challenge in diagnosis, treatment, and prevention for both diseases. We add to the literature on co-infection of P. falciparum malaria and COVID-19 and offer operational advice on diagnosis, prevention, and treatment for the co-infection.
Keywords: COVID-19; Plasmodium falciparum; SARS-CoV-2; Sub-Saharan Africa; co-infection; malaria.
【저자키워드】 COVID-19, SARS-CoV-2, malaria, sub-Saharan Africa, Co-infection, Plasmodium falciparum, 【초록키워드】 Treatment, coronavirus disease, Coronavirus disease 2019, Arbidol, coronavirus, pandemic, Diseases, Anxiety, Hospitalization, Lopinavir, Ritonavir, interferon, Diagnosis, severe acute respiratory syndrome Coronavirus, discharge, diazepam, malaria, China, sub-Saharan Africa, Co-infection, Insomnia, vital sign, health system, Evidence, Piperaquine, Plasmodium falciparum, Healthcare system, evidence of, no evidence of, zolpidem, Tablet, acute respiratory syndrome, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, Compound, tablets, P. falciparum, Plasmodium, LOPINAVIR AND RITONAVIR, offer, inflammatory reactions, Administered, thymosin, Mental, country, Paroxetine, hydrochloride, raise, dihydroartemisinin, Paroxetine Hydrochloride, Zolpidem Tartrate, tested, reported, the patient, discharged, Tartrate,